nach oben

Supportive Care in Cancer

Erschienen in:

25.10.2021 | Review Article

The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis

verfasst von: Shurui Wang, Ting Yang, Wanmin Qiang, Aomei Shen, Zihan Zhao, Huili Yang, Xiaofeng Liu

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Coexistence of frailty and breast cancer (BC) is related to a higher risk of hospitalization, mortality, and falls. Given the potential reversibility of frailty, investigating its epidemiology in BC is of great importance. However, estimates of the prevalence of frailty in BC patients vary considerably. We synthesized the existing body of literature on the prevalence of frailty among BC patients.

Methods

We searched English databases (Cochrane Library, PubMed, Medline, CINAHL, Embase, Scopus, and Web of Science) and Chinese databases (CNKI, WanFang, CBM, and VIP database) from the inception to April 15, 2021, and collected observational studies about the prevalence of frailty among BC patients. The robustness of the pooled estimates was validated by analysis of different subgroups, meta-regression, and sensitivity. All data were analyzed using Stata 15.1.

Results

In total, 4645 articles were screened and data from 24 studies involving 13,510 subjects were used in the meta-analysis. The prevalence of frailty among BC patients in individual studies varied from 5 to 71%. The pooled prevalence of frailty was 43% (95% confidence intervals (CI): 36% to 50%, I² = 98.4%, P < 0.05). Subgroup analyses revealed that the therapeutic method, frailty scales, age, frailty stage, regions, publication years, and study quality were associated with the prevalence of frailty among BC patients.

Conclusions

The prevalence of frailty among BC patients was relatively high, and the conditions of BC treatment can increase the risk of frailty. Understanding the effects of frailty on BC, especially in elderly patients, can provide the healthcare personnel with the theoretical basis for patients’ management and treatment.

Nur mit Berechtigung zugänglich

Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA (2005) Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol 34(2):405–412. https://doi.org/10.1093/ije/dyh414CrossRefPubMed

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, https://doi.org/10.3322/caac.21660. Advance online publication. https://doi.org/10.3322/caac.21660

DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69(6):438–451. https://doi.org/10.3322/caac.21583CrossRefPubMed

Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758–2765. https://doi.org/10.1200/JCO.2008.20.8983CrossRefPubMed

Cancer Research UK. Breast cancer incidence (invasive) statistics, 2019. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive#ref-1. (May 6, 2021)

Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, Ibrahim JG, Jolly TA, Williams G, Carey LA, Drobish A, Gordon BB, Alston S, Hurria A, Kleinhans K, Rudolph KL, Sharpless NE, Muss HB (2014) Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst 106(4):dju057. https://doi.org/10.1093/jnci/dju057CrossRefPubMedPubMedCentral

Armenian SH, Gibson CJ, Rockne RC, Ness KK (2019) Premature aging in young cancer survivors. J Natl Cancer Inst 111(3):226–232. https://doi.org/10.1093/jnci/djy229CrossRefPubMed

Alfano CM, Peng J, Andridge RR, Lindgren ME, Povoski SP, Lipari AM, Agnese DM, Farrar WB, Yee LD, Carson WE 3rd, Kiecolt-Glaser JK (2017) Inflammatory cytokines and comorbidity development in breast cancer survivors versus noncancer controls: evidence for accelerated aging? J Clin Oncol 35(2):149–156. https://doi.org/10.1200/JCO.2016.67.1883CrossRefPubMed

Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, Fuldner R, Ferrucci L, Gallicchio L, Gavrilov L, Gavrilova N, Green PA, Jhappan C, Kohanski R, Krull K, Mandelblatt J, Ness KK, O'Mara A, Price N, Schrack J … Hurria A (2019) Measuring aging and identifying aging phenotypes in cancer survivors. J Natl Cancer Inst 111(12):1245 1254 https://doi.org/10.1093/jnci/djz136

10.

Ness KK, Wogksch MD (2020) Frailty and aging in cancer survivors. Transl Res 221:65–82. https://doi.org/10.1016/j.trsl.2020.03.013CrossRefPubMedPubMedCentral

11.

Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E, Colloca G, Flamaing J, Karnakis T, Kenis C, Audisio RA, Mohile S, Repetto L, Van Leeuwen B, Milisen K, Hurria A (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595–2603. https://doi.org/10.1200/JCO.2013.54.8347CrossRefPubMedPubMedCentral

12.

Cohen HJ, Smith D, Sun CL, Tew W, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Filo J, Katheria V, Hurria A, Cancer and Aging Research Group (2016) Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. Cancer 122(24):3865–3872. https://doi.org/10.1002/cncr.30269CrossRefPubMed

13.

Rockwood K, Howlett SE (2018) Fifteen years of progress in understanding frailty and health in aging. BMC Med 16(1):220. https://doi.org/10.1186/s12916-018-1223-3CrossRefPubMedPubMedCentral

14.

Kirkhus L, Šaltytė Benth J, Rostoft S, Grønberg BH, Hjermstad MJ, Selbæk G, Wyller TB, Harneshaug M, Jordhøy MS (2017) Geriatric assessment is superior to oncologists’ clinical judgement in identifying frailty. Br J Cancer 117(4):470–477. https://doi.org/10.1038/bjc.2017.202CrossRefPubMedPubMedCentral

15.

Enoka RM, Duchateau J (2016) Translating fatigue to human performance. Med Sci Sports Exerc 48(11):2228–2238. https://doi.org/10.1249/MSS.0000000000000929CrossRefPubMedPubMedCentral

16.

Brownstein CG, Rimaud D, Singh B, Fruleux-Santos LA, Sorg M, Micklewright D, Millet GY (2021) French translation and validation of the rating-of-fatigue scale. Sports Med Open 7(1):25. https://doi.org/10.1186/s40798-021-00316-8CrossRefPubMedPubMedCentral

17.

Xue QL, Bandeen-Roche K, Varadhan R, Zhou J, Fried LP (2008) Initial manifestations of frailty criteria and the development of frailty phenotype in the Women’s Health and Aging Study II. J Gerontol A Biol Sci Med Sci 63(9):984–990. https://doi.org/10.1093/gerona/63.9.984CrossRefPubMed

18.

Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146–M156. https://doi.org/10.1093/gerona/56.3.m146CrossRefPubMed

19.

Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J (2013) Frailty consensus: a call to action. J Am Med Dir Assoc 14(6):392–397. https://doi.org/10.1016/j.jamda.2013.03.022CrossRefPubMedPubMedCentral

20.

Mandelblatt JS, Cai L, Luta G, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A (2017) Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat 164(1):107–117. https://doi.org/10.1007/s10549-017-4222-8CrossRefPubMedPubMedCentral

21.

Williams GR, Deal AM, Sanoff HK, Nyrop KA, Guerard EJ, Pergolotti M, Shachar SS, Reeve BB, Bensen JT, Choi SK, Muss HB (2019) Frailty and health-related quality of life in older women with breast cancer. Support Care Cancer 27(7):2693–2698. https://doi.org/10.1007/s00520-018-4558-6CrossRefPubMed

22.

Morgan JL, George J, Holmes G, Martin C, Reed M, Ward S, Walters SJ, Cheung KL, Audisio RA, Wyld L, Bridging the Age Gap Trial Management Team (2020) Breast cancer surgery in older women: outcomes of the Bridging Age Gap in Breast Cancer study. Br J Surg 107(11):1468–1479. https://doi.org/10.1002/bjs.11617CrossRefPubMed

23.

Scheepers E, van der Molen LF, van den Bos F, Burgmans JP, van Huis-Tanja LH, Hamaker ME (2021) The G8 frailty screening tool and the decision-making process in older breast cancer patients. Eur J Cancer Care 30(1):e13357. https://doi.org/10.1111/ecc.13357CrossRef

24.

Hartley P, Adamson J, Cunningham C, Embleton G, Romero-Ortuno R (2017) Clinical frailty and functional trajectories in hospitalized older adults: a retrospective observational study. Geriatr Gerontol Int 17(7):1063–1068. https://doi.org/10.1111/ggi.12827CrossRefPubMed

25.

Kua J, Ramason R, Rajamoney G, Chong MS (2016) Which frailty measure is a good predictor of early post-operative complications in elderly hip fracture patients? Arch Orthop Trauma Surg 136(5):639–647. https://doi.org/10.1007/s00402-016-2435-7CrossRefPubMed

26.

Fan J, Yu C, Guo Y, Bian Z, Sun Z, Yang L, Chen Y, Du H, Li Z, Lei Y, Sun D, Clarke R, Chen J, Chen Z, Lv J, Li L, China Kadoorie Biobank Collaborative Group (2020) Frailty index and all-cause and cause-specific mortality in Chinese adults: a prospective cohort study. The Lancet. Public health 5(12):e650–e660. https://doi.org/10.1016/S2468-2667(20)30113-4CrossRefPubMedPubMedCentral

27.

Magnuson A, Lei L, Gilmore N, Kleckner AS, Lin FV, Ferguson R, Hurria A, Wittink MN, Esparaz BT, Giguere JK, Misleh J, Bautista J, Mohile SG, Janelsins MC (2019) Longitudinal relationship between frailty and cognition in patients 50 years and older with breast cancer. J Am Geriatr Soc 67(5):928–936. https://doi.org/10.1111/jgs.15934CrossRefPubMedPubMedCentral

28.

Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van Den Bulck H, Smeets A, Bechter O, Bailur JK, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem GE, Wildiers H (2016) The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget 7(21):29977–29988. https://doi.org/10.18632/oncotarget.8796CrossRefPubMedPubMedCentral

29.

Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, Le-Rademacher J, Jatoi A, Filo J, Mandelblatt J, Lafky JM, Kimmick G, Klepin HD, Freedman RA, Burstein H, Gralow J, Wolff AC, Magrinat G, Barginear M, Muss H (2019) Functional decline and resilience in older women receiving adjuvant chemotherapy for breast cancer. J Am Geriatr Soc 67(5):920–927. https://doi.org/10.1111/jgs.15493CrossRefPubMed

30.

Kirkhus L, Šaltytė Benth J, Grønberg BH, Hjermstad MJ, Rostoft S, Harneshaug M, Selbæk G, Wyller TB, Jordhøy MS (2019) Frailty identified by geriatric assessment is associated with poor functioning, high symptom burden and increased risk of physical decline in older cancer patients: prospective observational study. Palliat Med 33(3):312–322. https://doi.org/10.1177/0269216319825972CrossRefPubMedPubMedCentral

31.

Gilmore N, Kadambi S, Lei L, Loh KP, Mohamed M, Magnuson A, Cole S, Esparaz BT, Giguere JK, Mohile S, Janelsins M (2020) Associations of inflammation with frailty in patients with breast cancer aged 50 and over receiving chemotherapy. J Geriatr Oncol 11(3):423–430. https://doi.org/10.1016/j.jgo.2019.04.001CrossRefPubMed

32.

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., McGuinness, L. A., … Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1), 89. https://doi.org/10.1186/s13643-021-01626-4

33.

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al (2000) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Available online at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed April 24, 2021)

34.

Rostom A, Dube C, Cranney A, et al.Celiac Disease.Rockville (MD) :Agency for Healthcare Research and Quality (US) ;2004Sep. (Evidence Reports/Technology Assessments, No.104.) Appendix D. Quality assessment forms. http://www.ncbi.nlm.nih.gov/books/NBK35156

35.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed.) 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557CrossRef

36.

Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54(10):1046–1055. https://doi.org/10.1016/s0895-4356(01)00377-8CrossRefPubMed

37.

Hollenberg DC, Menjak IB, Mehta R, Bristow B, Trudeau ME, Gibson L, Neve M, Norris M, Pasetka M, Rice K, McCullock F, Wright FC, Szumacher E (2019) Gait speed vs. VES-13: a pilot study comparing screening tools to determine the need for a comprehensive geriatric assessment in senior women with breast cancer. J Med Imaging Radiat Sci 50(4):551–556. https://doi.org/10.1016/j.jmir.2019.06.053CrossRefPubMed

38.

Hamaker ME, Seynaeve C, Wymenga AN, van Tinteren H, Nortier JW, Maartense E, de Graaf H, de Jongh FE, Braun JJ, Los M, Schrama JG, van Leeuwen-Stok AE, de Groot SM, Smorenburg CH (2014) Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists’ group. Breast (Edinburgh, Scotland) 23(1):81–87. https://doi.org/10.1016/j.breast.2013.11.004CrossRef

39.

Domínguez-Alonso JA, Conde-Estévez D, Bosch D, Pi-Figueras M, Tusquets I (2021) Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything? Clin Transl Oncol 23(1):65–73. https://doi.org/10.1007/s12094-020-02386-8CrossRefPubMed

40.

Mandelblatt, J. S., Small, B. J., Luta, G., Hurria, A., Jim, H., McDonald, B. C., Graham, D., Zhou, X., Clapp, J., Zhai, W., Breen, E., Carroll, J. E., Denduluri, N., Dilawari, A., Extermann, M., Isaacs, C., Jacobsen, P. B., Kobayashi, L. C., Holohan Nudelman, K., Root, J., … Ahles, T. (2018). Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study. Journal of clinical oncology, 36(32), JCO1800140. Advance online publication. https://doi.org/10.1200/JCO.18.00140

41.

Gironés R, Torregrosa D, Díaz-Beveridge R (2010) Comorbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience. Crit Rev Oncol Hematol 73(3):236–245. https://doi.org/10.1016/j.critrevonc.2009.08.002CrossRefPubMed

42.

Okonji DO, Sinha R, Phillips I, Fatz D, Ring A (2017) Comprehensive geriatric assessment in 326 older women with early breast cancer. Br J Cancer 117(7):925–931. https://doi.org/10.1038/bjc.2017.257CrossRefPubMedPubMedCentral

43.

Mandelblatt, J. S., Zhou, X., Small, B. J., Ahn, J., Zhai, W., Ahles, T., Extermann, M., Graham, D., Jacobsen, P. B., Jim, H., McDonald, B. C., Patel, S., Root, J. C., Saykin, A. J., Cohen, H. J., & Carroll, J. E. (2021). Deficit accumulation frailty trajectories of older breast cancer survivors and Non-cancer controls: the thinking and living with cancer study. Journal of the National Cancer Institute, djab003. Advance online publication. https://doi.org/10.1093/jnci/djab003

44.

Bellieni A, Fusco D, Sanchez AM, Franceschini G, Di Capua B, Allocca E, Di Stasio E, Marazzi F, Tagliaferri L, Masetti R, Bernabei R, Colloca GF (2021) Different impact of definitions of sarcopenia in defining frailty status in a population of older women with early breast cancer. Journal of personalized medicine 11(4):243. https://doi.org/10.3390/jpm11040243CrossRefPubMedPubMedCentral

45.

Bennett JA, Winters-Stone KM, Dobek J, Nail LM (2013) Frailty in older breast cancer survivors: age, prevalence, and associated factors. Oncol Nurs Forum 40(3):E126–E134. https://doi.org/10.1188/13.ONF.E126-E134CrossRefPubMedPubMedCentral

46.

Guerard EJ, Deal AM, Chang Y, Williams GR, Nyrop KA, Pergolotti M, Muss HB, Sanoff HK, Lund JL (2017) Frailty index developed from a cancer-specific geriatric assessment and the association with mortality among older adults with cancer. Journal of the National Comprehensive Cancer Network : JNCCN 15(7):894–902. https://doi.org/10.6004/jnccn.2017.0122CrossRefPubMed

47.

Mandelblatt JS, Clapp JD, Luta G, Faul LA, Tallarico MD, McClendon TD, Whitley JA, Cai L, Ahles TA, Stern RA, Jacobsen PB, Small BJ, Pitcher BN, Dura-Fernandis E, Muss HB, Hurria A, Cohen HJ, Isaacs C (2016) Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer 122(22):3555–3563. https://doi.org/10.1002/cncr.30208CrossRefPubMed

48.

Corona G, Polesel J, Fratino L, Miolo G, Rizzolio F, Crivellari D, Addobbati R, Cervo S, Toffoli G (2014) Metabolomics biomarkers of frailty in elderly breast cancer patients. J Cell Physiol 229(7):898–902. https://doi.org/10.1002/jcp.24520CrossRefPubMed

49.

Aaldriks AA, Giltay EJ, le Cessie S, van der Geest LG, Portielje JE, Tanis BC, Nortier JW, Maartense E (2013) Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy. Breast (Edinburgh, Scotland) 22(5):753–760. https://doi.org/10.1016/j.breast.2013.01.011CrossRef

50.

Jauhari Y, Dodwell D, Gannon MR, Horgan K, Clements K, Medina J, Cromwell DA (2021) The influence of age, comorbidity and frailty on treatment with surgery and systemic therapy in older women with operable triple negative breast cancer (TNBC) in England: a population-based cohort study. Eur J Surg Oncol 47(2):251–260. https://doi.org/10.1016/j.ejso.2020.09.022CrossRefPubMed

51.

Gilmore N, Mohile S, Lei L, Culakova E, Mohamed M, Magnuson A, Loh KP, Maggiore R, Belcher E, Conlin A, Weiselberg L, Ontko M, Janelsins M (2021) The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy. Breast Cancer Res 23(1):19. https://doi.org/10.1186/s13058-021-01388-wCrossRefPubMedPubMedCentral

52.

Middelburg JG, Mast ME, de Kroon M, Jobsen JJ, Rozema T, Maas H, Baartman EA, Geijsen D, van der Leest AH, van den Bongard DJ, van Loon J, Budiharto T, Coebergh JW, Aarts MJ, Struikmans H, LPRO (Dutch National Organization for Radiotherapy in the Elderly) (2017) Timed Get Up and Go test and Geriatric 8 scores and the association with (chemo-)radiation therapy noncompliance and acute toxicity in elderly cancer patients. Int J Radiat Oncol Biol Phys 98(4):843–849. https://doi.org/10.1016/j.ijrobp.2017.01.211CrossRefPubMed

53.

Speigl L, Grieb A, Janssen N, Hatse S, Brouwers B, Smeets A, Floris G, Bailur JK, Kenis C, Neven P, Wildiers H, Pawelec G, Shipp C (2018) Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. Journal of geriatric oncology 9(6):606–612. https://doi.org/10.1016/j.jgo.2018.03.021CrossRefPubMed

54.

Molina-Garrido MJ, Guillen-Ponce C (2011) Comparison of two frailty screening tools in older women with early breast cancer. Crit Rev Oncol Hematol 79(1):51–64. https://doi.org/10.1016/j.critrevonc.2010.06.004CrossRefPubMed

55.

Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, Young J (2015) The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 26(6):1091–1101. https://doi.org/10.1093/annonc/mdu540CrossRefPubMed

56.

Kojima G, Iliffe S, Walters K (2018) Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age Ageing 47(2):193–200. https://doi.org/10.1093/ageing/afx162CrossRefPubMed

57.

Ethun CG, Bilen MA, Jani AB, Maithel SK, Ogan K, Master VA (2017) Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin 67(5):362–377. https://doi.org/10.3322/caac.21406CrossRefPubMed

58.

Chang S, Goldstein NE, Dharmarajan KV (2017) Managing an older adult with cancer: considerations for radiation oncologists. Biomed Res Int 2017:1695101. https://doi.org/10.1155/2017/1695101CrossRefPubMedPubMedCentral

59.

Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, Bandeen-Roche K, Varadhan R (2016) Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev 26:53–61. https://doi.org/10.1016/j.arr.2015.12.003CrossRefPubMed

60.

Di Donato V, Caruso G, Bogani G, Giannini A, D’Oria O, Perniola G, Palaia I, Plotti F, Angioli R, Muzii L, Benedetti Panici P (2021) Preoperative frailty assessment in patients undergoing gynecologic oncology surgery: a systematic review. Gynecol Oncol 161(1):11–19. https://doi.org/10.1016/j.ygyno.2020.12.030CrossRefPubMed

61.

Payne CF, Wade A, Kabudula CW, Davies JI, Chang AY, Gomez-Olive FX, Kahn K, Berkman LF, Tollman SM, Salomon JA, Witham MD (2017) Prevalence and correlates of frailty in an older rural African population: findings from the HAALSI cohort study. BMC Geriatr 17(1):293. https://doi.org/10.1186/s12877-017-0694-yCrossRefPubMedPubMedCentral

62.

Collard RM, Boter H, Schoevers RA, Oude Voshaar RC (2012) Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc 60(8):1487–1492. https://doi.org/10.1111/j.1532-5415.2012.04054.xCrossRefPubMed

63.

Majid Z, Welch C, Davies J, Jackson T (2020) Global frailty: the role of ethnicity, migration and socioeconomic factors. Maturitas 139:33–41. https://doi.org/10.1016/j.maturitas.2020.05.010CrossRefPubMedPubMedCentral

64.

Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP (2019) Frailty: implications for clinical practice and public health. Lancet (London, England) 394(10206):1365–1375. https://doi.org/10.1016/S0140-6736(19)31786-6CrossRef

65.

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet (London, England) 352(9128):609–613. https://doi.org/10.1016/S0140-6736(98)01085-XCrossRef

66.

Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135(11):982–989. https://doi.org/10.7326/0003-4819-135-11-200112040-00010CrossRefPubMed

67.

Pugh RJ, Ellison A, Pye K, Subbe CP, Thorpe CM, Lone NI, Clegg A (2018) Feasibility and reliability of frailty assessment in the critically ill: a systematic review. Critical care (London, England) 22(1):49. https://doi.org/10.1186/s13054-018-1953-9CrossRef

68.

Ng JK, Kwan BC, Chow KM, Cheng PM, Law MC, Pang WF, Leung CB, Li PK, Szeto CC (2016) Frailty in Chinese peritoneal dialysis patients: prevalence and prognostic significance. Kidney Blood Press Res 41(6):736–745. https://doi.org/10.1159/000450563CrossRefPubMed

69.

Kong LN, Lyu Q, Yao HY, Yang L, Chen SZ (2021) The prevalence of frailty among community-dwelling older adults with diabetes: a meta-analysis. Int J Nurs Stud 119:103952. https://doi.org/10.1016/j.ijnurstu.2021.103952CrossRefPubMed

70.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655CrossRefPubMed

Titel: The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis
verfasst von: Shurui Wang
Ting Yang
Wanmin Qiang
Aomei Shen
Zihan Zhao
Huili Yang
Xiaofeng Liu
Publikationsdatum: 25.10.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 4/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06641-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors

Deprescribing in palliative patients with cancer: a concise review of tools and guidelines

Early versus the traditional start of oral intake following esophagectomy for esophageal cancer: a systematic review and meta-analysis

Effects of sleep interventions on cancer-related fatigue and quality of life in cancer patients: a systematic review and meta-analysis

Getting back on track: a group psychoeducational intervention for patients and families living with head and neck cancer

The dynamic relationship between cancer and employment-related financial toxicity: an in-depth qualitative study of 21 Australian cancer survivor experiences and preferences for support

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie